Holen Sie sich die Stockscreener-App
6.88
3.93%
0.26
Handel nachbörslich:
6.88
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
SLDB Stock Price, Quote & Chart | SOLID BIOSCIENCES INC (NASDAQ:SLDB) - ChartMill
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months? - Insider Monkey
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
SLDB Reiterated by Wedbush -- Price Target Maintained at $16.00 - GuruFocus
Solid Biosciences Price Target Maintained With a $16.00/Share by Wedbush - Moomoo
SLDB: Citigroup Lowers Price Target but Maintains Buy Rating | S - GuruFocus
H.C. Wainwright Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Citigroup Maintains Solid Biosciences (SLDB) Buy Recommendation - MSN
Solid Biosciences stock (US8317541063): Piper Sandler raises price target to $18 - AD HOC NEWS
Solid Biosciences Inc. to host webinar on SGT-003 gene therapy for Duchenne - Traders Union
Number of shareholders of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Wedbush Adjusts Price Target on Solid Biosciences to $16 From $17, Maintains Outperform Rating - Moomoo
SLDB Maintained by Piper Sandler -- Price Target Raised to $18 - GuruFocus
Wedbush Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $16 - Moomoo
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences (SLDB) boosts cash to $380.7M while Q1 net loss widens - Stock Titan
Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
TradingKey - TradingKey
Solid Biosciences Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
SLDB SEC FilingsSolid Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating - Moomoo
Solid Biosciences begins phase 3 trial for Duchenne therapy By Investing.com - Investing.com South Africa
Solid Biosciences begins phase 3 trial for Duchenne therapy - Investing.com
A Duchenne treatment reaches Phase 3 after 46 patients dosed - Stock Titan
Solid Biosciences Doses First Participant in Phase 3 IMPACT - GlobeNewswire
Solid Biosciences Chief Medical Officer presents targeted therapy delivery approach at Boston biotech conference - Traders Union
SLDB: JP Morgan Raises Price Target to $12 with Overweight Ratin - GuruFocus
Invus and affiliates hold 9.99% of Solid Biosciences (NASDAQ: SLDB) via warrants and shares - Stock Titan
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
One new Solid Biosciences employee gets 8,070 stock units - Stock Titan
SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target - GuruFocus
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy - marketscreener.com
Solid Biosciences to Showcase a Large Presence at the 29th - GlobeNewswire
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Solid Biosciences receives EU orphan drug status for SGT-003 - Investing.com UK
Solid Biosciences (SLDB) Receives Orphan Drug Designation for SG - GuruFocus
Solid Biosciences receives EU orphan drug status for SGT-003 By Investing.com - Investing.com South Africa
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):